|
Dr. Dillberger is a preclinical development consultant specializing in the application of pharmacology, toxicology, and pathology expertise to the safety evaluation of drugs, devices, and biologics. His clients include biopharmaceutical companies in the United States, Korea, Japan, Italy, and New Zealand, as well as nonprofit foundations and investment firms with pharmaceutical company portfolios.
Over his 16 years in the pharmaceutical industry, Dr. Dillberger has held positions of increasing responsibility at Marion Merrell Dow, GlaxoWellcome, Triangle Pharmaceuticals, and Charles River Laboratories. He has served as Head of U.S. Pathology, Director of U.S.-Based Development Projects, Worldwide Specialist in Oncology Drug Projects for GlaxoWellcome, and as Director of Toxicology at Triangle Pharmaceuticals. Dr. Dillberger has prepared safety evaluation packages for numerous clinical trial and marketing applications in the United States and Europe, including the recently approved NDA for the antiretroviral drug Coviracil�.
Dr. Dillberger received his D.V.M. degree from Iowa State University in 1979, completed a three-year residency in Comparative Pathology at the University of Miami School of Medicine and Papanicolaou Cancer Research Institute in 1986, and received a Ph.D. degree in Pathology and Environmental Toxicology from Michigan State University in 1989 for research into the molecular mechanisms of carcinogenesis. He was certified in Veterinary Pathology by the American College of Veterinary Pathologists in 1987 and in Toxicology by the American Board of Toxicology in 1992. In 2001, he became one of a handful of pathologists accepted as a Fellow in the International Academy of Toxicologic Pathology. He is the author of numerous scientific papers and a book chapter entitled �Nonclinical Development of Drugs and Biologics: Pharmacology and Toxicology�. He serves as reviewer for Antimicrobial Agents and Chemotherapy and is presently serving a second term on the editorial board of Veterinary Pathology. | 